GL Capital and Zylox Tonbridge Back Lifetech to Build China Vascular Device Platform
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.5 Articles
5 Articles
Zylox-Tonbridge And GL Capital Announce Strategic Investment In LifeTech Scientific To Build A Leading Vascular And Structural Heart Intervention Platform
The investment is expected to bring together Zylox-Tonbridge's peripheral vascular and neurovascular businesses with LifeTech's aortic and structural heart businesses, creating a comprehensive portfolio across four key therapeutic areas <p>The post Zylox-Tonbridge and GL Capital Announce Strategic Investment in LifeTech Scientific to Build a Leading Vascular and Structural Heart Intervention Platform first appeared on Medical Device News Magazin…
Linklaters Advises Zylox-tonbridge On Acquisition Of Equity Interest In Lifetech Scientific Corporation And New Share Issuance.
Linklaters has advised Zylox-Tonbridge Medical Technology Co., Ltd. (Zylox-Tonbridge) on its acquisition of an equity interest in LifeTech Scientific Corporation (LifeTech) via a joint venture with GL Capital and related issuance of new H shares to GL Capital. Upon completion […]
GL Capital and Zylox Tonbridge Back Lifetech to Build China Vascular Device Platform
Lifetech Scientific Corporation said it had brought in a joint strategic investment from GL Capital and Zylox-Tonbridge Medical Technology, a deal aimed at building a leading Chinese platform for vascular and structural heart disease interventions. The Hong Kong-listed medical device company announced on Nov. 6, 2026, that the investment would combine industrial and capital resources across the three parties. The investment is designed to integr…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
